p53 gene therapy - Shenzhen SiBiono GeneTech

Drug Profile

p53 gene therapy - Shenzhen SiBiono GeneTech

Alternative Names: Gendicine; p53 gene therapy - SiBiono; rAD-p53 - Shenzhen SiBiono GenTech; Recombinant Ad-p53 anti-cancer injection - Sibiono

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shenzhen SiBiono GeneTech
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action Tumour suppressor protein p53 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Head and neck cancer
  • Phase II Hepatocellular carcinoma

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Head-and-neck-cancer in India (Intratumoural, Injection)
  • 28 Apr 2015 Shenzhen SiBiono GeneTech plans a phase II trial for Ovarian Cancer, fallopian tube cancer and peritoneal cancer in China (NCT02435186)
  • 24 Apr 2015 Shenzhen SiBiono GeneTech plans a phase II trial for Malignant pleural effusion in China (NCT02429726)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top